AviGenics
Stage
Grant | AliveTotal Raised
$25.57MLast Raised
$100K | 16 yrs agoAbout AviGenics
Avigenics is a company that received a SBIR Phase I grant for a project entitled: Production of Transgenic Poultry Resistant to Avian Influenza Infection by RNAi. Their project generates transgenic poultry resistant to avian influenza (AI) virus through RNA interference (RNAi) technology. Poultry are vulnerable to AI infections that can rapidly reach mortality rates approaching 100%. Current vaccines provide only limited protection, with prophylaxis based on surveillance and diagnosis, followed by rapid depopulation and disposal of infected or exposed birds and quarantine and disinfection of farms and equipment. RNAi technology is a new strategy that could be applied to the inhibition of AI virus replication, representing a paradigm shift in the way to deal with the challenges of AI. Phase I objectives are (i) to generate ALV vectors hosting short interfering RNA (siRNA), (ii) establish stable cell lines hosting siRNAs vectors and (iii) test the efficacy of siRNAs against AI viruses. Three siRNAs shown to effectively inhibit AI viruses will be used to generate cell lines, which will be challenged with 5 different AI viruses to determine whether these vectors, when integrated into the avian genome, can effectively inhibit AI viruses. The broader impact of this research will be to improve the biosecurity of biopharmaceutical production in poultry as the avian influenza virus spreads and well as potentially protecting the food supply from natural as well as bioterrorist threats should these transgenic chickens gain wide approval in the marketplace.
Missing: AviGenics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: AviGenics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing AviGenics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
AviGenics is included in 2 Expert Collections, including Food & Beverage .
Food & Beverage
133 items
Market Research & Consumer Insights
717 items
This collection is comprised of companies using tech to better identify emerging trends and improve product development. It also includes companies helping brands and retailers conduct market research to learn about target shoppers, like their preferences, habits, and behaviors.
AviGenics Patents
AviGenics has filed 1 patent.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
1/4/2007 | 3/24/2009 | Molecular biology, Biotechnology, Genetics, RNA, Molecular biology techniques | Grant |
Application Date | 1/4/2007 |
|---|---|
Grant Date | 3/24/2009 |
Title | |
Related Topics | Molecular biology, Biotechnology, Genetics, RNA, Molecular biology techniques |
Status | Grant |
Latest AviGenics News
Nov 26, 2016
Advertisement Topics Track topics on Twitter Track topics that are important to you Printed From BioPortfolio.com Synageva BioPharma Corp. formerly AviGenics, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 13:48 EST 26 Nov 2016 | BioPortfolio Reports Home » Topics » Alliances, mergers acquisitions and partnerships » Latest News » Synageva BioPharma Corp. formerly AviGenics, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 Project Synopsis: Datamonitor's Company Mergers Acquisitions MA, Partnerships Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Project Description: Datamonitors' Synageva BioPharma Corp. formerly AviGenics, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Synageva BioPharma Corp. formerly AviGenics, Inc. since January 2007. Scope: Provides intelligence on Synageva BioPharma Corp. formerly AviGenics, Inc.'s MA, strategic partnerships and alliances, capital raising and private equity transactions. Detailed reports of various financial transactions undertaken by Synageva BioPharma Corp. formerly AviGenics, Inc. and its subsidiaries since 2007. Information about key financial and legal advisors for Synageva BioPharma Corp. formerly AviGenics, Inc.'s financial deals transactions. Financial deals tables and charts covering deal value and volumes trend, deal types and geographybased deal activity. Highlights: This report includes Synageva BioPharma Corp. formerly AviGenics, Inc.'s contact information and business summary, tables, graphs, a list of partners and targets, a breakdown of financial and legal advisors, deal types, top deals by deal value, detailed deal reports, and descriptions and contact details of the partner, target, investor, and vendor firms, where disclosed. The profile also includes detailed deal reports for all MA, private equity, public offering, venture financing, partnership and divestment transactions undertaken by Synageva BioPharma Corp. formerly AviGenics, Inc.. These deal reports contain information about target company financials, sources of financing, method of payment, deal values, and advisors for various parties, where disclosed. Reasons to Purchase: Access comprehensive financial deals data along with charts and graph covering MA, private equity, and partnerships and alliances. Form an independent opinion about Synageva BioPharma Corp. formerly AviGenics, Inc.'s growth strategies through the organic and inorganic activities undertaken since 2007. Track your competitors' business structure and growth strategies. Related Biotechnology, Pharmaceutical and Healthcare News
AviGenics Frequently Asked Questions (FAQ)
Where is AviGenics's headquarters?
AviGenics's headquarters is located at 111 Riverbend Rd., Athens.
What is AviGenics's latest funding round?
AviGenics's latest funding round is Grant.
How much did AviGenics raise?
AviGenics raised a total of $25.57M.
Who are the investors of AviGenics?
Investors of AviGenics include National Science Foundation.
Who are AviGenics's competitors?
Competitors of AviGenics include Biolog, Sirnaomics, Clinipace, GangaGen, Achillion Pharmaceuticals and 16 more.
Compare AviGenics to Competitors
Spider Biotech is a young and dynamic biotechnology company founded in 2005 with the aim of developing synthetic peptide therapeutics. nnAntimicrobial host-defense peptides have been recognized as an important part of innate immunity found throughout the evolutionary tree that defend against invading bacteria, viruses, and fungi through membrane or metabolic disruption. Inspired by natural antimicrobial peptides, Spider Biotech is developing a library of bioactive peptides and lipopeptides active against bacterial and viral infections. nSpiderBiotech's business strategy is to remain focused on the discovery and early-stage development of drug candidates and seek to establish partnerships with pharmaceutical companies for late-stage development and commercialization of its products. nnThe firm aims to become leader in developing peptide-based antiinfectives to address the urgent and global problem posed by resistance to conventional treatments. The Company is headquartered at the Bioindustry Park del Canavese (Turin, Italy).
Pulmotect develops host-directed or pathogen-agnostic products to reduce morbidity and mortality in patients at risk of severe respiratory diseases. It offers immunomodulatory and pathogen-agnostic approaches to prevent and treat respiratory complications. The company was founded in 2007 and is based in Houston, Texas.
Biolog specializes in microbial identification, phenotypic cell profiling, and metabolic fingerprinting for microbial and mammalian cells. The company’s products enable the identification of thousands of species of bacteria, yeast, and fungi, as well as the characterization of human cells and mitochondria. Biolog's products are available worldwide, either directly from the company or through its extensive network of international distributors. The company was founded in 1984 and is based in Hayward, California.
Oligomerix is a clinical-stage biotechnology company. It focuses on developing disease-modifying therapeutics for neurodegenerative diseases characterized by the aberrant tau protein, ranging from tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. The firm serves clients in the healthcare sector. Oligomerix was founded in 2006 and is based in West Harrison, New York.
Emiliem operates as a biopharmaceutical company that is engaged in early oncology R&D. The company develops Molecular Targeted Therapeutics (MTTs) for oncology and other indications. MTTs are therapeutic agents that target biologically important processes central to the development and progression of cancer and other diseases. The company's clinical development strategy is focused on identifying patients most likely to respond to treatment and monitoring clinical outcome with specific biomarkers used as diagnostic assays.
Adjuvant Research Services is a provider of nationwide clinical development temporary staffing for the biopharmaceutical industry. The company's consultants are supplied to the company's biopharmaceutical customers for regional monitoring, in-house monitoring, auditing, medical writing (including manuscript and protocol writing), project management, medical monitoring and pharmacovigilence services).
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.